Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Product Candidates during the Upcoming ASH Annual Meeting
Publié le 05 novembre 2015
New York, November 5, 2015 – Cellectis (Alternext: ALCLS – Nasdaq: CLLS) today announced that data on its engineered allogeneic CAR T-Cell product candidates, UCARTCS1 and UCART123, will be presented during the 2015 American Society of Hematology Annual Meeting. A poster and an oral presentation will be presented during this event.
Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM)
Oral presentation
Session Name: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutics and the Impact of the Microenvironment
Presentation Time: Saturday, December 5, 2015 at 2:15 PM
TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML)
Poster presentation
Session Name: Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Presentation Time: Sunday, December 6, 2015 from 6:00 PM to 8:00 PM